Expression of ASPP2k, a dominant-negative, oncogenic isoform of the Apoptosis-Stimulating Protein of p53-2 (ASPP2), accounts for a more aggressive tumorbiology in HER2+breast cancer

被引：0
|
作者：
Beck, I [1 ]
Ruiba, A. [1 ]
Sommer, I [1 ]
Aellig, V [1 ]
Ahrens, A. -L [1 ]
Kampa-Schittenhelm, K. [1 ,2 ]
机构：
[1] Kantonsspital St Gallen, Med Onkol & Hamatol, St Gallen, Switzerland
[2] Univ Klinikum Tubingen, Innere Med 2, Hamatol Onkol Klin Immunol & Rheumatol, Tubingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V645
引用
收藏
页码：98 / 98
页数：1
相关论文
共 35 条
  • [1] ASPP2k, an oncogenic splice variant of the Apoptosis-Stimulating Protein of p53-2 (ASPP2) promotes proliferation and invasion in sarcoma
    Tsintari, V
    Walter, B.
    Hinterleitner, C.
    Schittenhelm, M. M.
    Kampa-Schittenhelm, K. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 125 - 125
  • [2] ONCOGENIC ASPP2KAPPA(K), A DOMINANT-NEGATIVE ISOFORM OF THE APOPTOSIS STIMULATING PROTEIN OF P53-2 (ASPP2) PROMOTES CLASSICAL HALLMARKS OF CANCER IN GLIOBLASTOMA
    Hafner, M.
    Ruiba, A.
    Kampa, L.
    Sommer, I.
    Ahrens, A.
    Kalin, V.
    Zeitlberger, A.
    Buchauer, K.
    Plasswilm, L.
    Hundsberger, T.
    Neidert, M.
    Schittenhelm, M. M.
    Kampa-Schittenhelm, K. M.
    NEURO-ONCOLOGY, 2023, 25
  • [3] Detection and characterization of a dominant-negative oncogenic splice variant of the Apoptosis-Stimulating Protein of p53-2 (ASPP2) in colorectal cancer (CRC)
    Rieger, I
    Tsintari, V
    Schittenhelm, M. M.
    Kampa-Schittenhelm, K. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 286 - 287
  • [4] ASPP2 k, a Dominant-Negative Splicing Variant of the Apoptosis-Stimulating Protein of p53-2 (ASPP2), Modulates Treatment Response Towards BCL-Signaling Inhibitors in Acute Myeloid Leukemia
    Schittenhelm, Marcus M.
    Tsintari, Vasileia
    Froehlich, Rebecca
    Kampa-Schittenhelm, Kerstin Maria
    BLOOD, 2021, 138
  • [5] Detection and characterisation of a dominant-negative, oncogenic splicing variant of the Apoptosis-StimulatingProtein of p53-2 (ASPP2) in triple negative breast cancer (TNBC)
    Ahrens, A. -L
    Tsintari, V
    Jochum, W.
    Schittenhelm, M. M.
    Kampa-Schittenhelm, K. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 91 - 91
  • [6] Inhibition of oncogenic ASPP2kappa(k), a dominant-negative isoform of the tumorsuppressor ASPP2, results in reactivation of p53 in glioblastoma
    Hafner, Marlon
    Ruiba, Alessia
    Kampa, Leonie
    Kalin, Vincent
    Neidert, Marian
    Buchauer, Konrad
    Henke, Guido
    Plasswilm, Ludwig
    Schittenhelmn, Marcus M.
    Kampa-Schittenhelm, Kerstin M.
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Detection of a C-terminally truncated, dominant-negative, oncogenic splice variant of the Apoptosis-Stimulating-Protein of p53-2 (ASPP2) in sarcoma
    Kampa-Schittenhelm, K. M.
    Walter, B.
    Hinterleitner, C.
    Kopp, H. G.
    Kanz, L.
    Schittenhelm, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 256 - 256
  • [8] Insights into the role of ASPP2 (Apoptosis stimulating protein of p53-2) in lymphomagenesis
    Kampa-Schittenhelm, K. M.
    Mueller, S.
    Bonin, M.
    Kanz, L.
    Schittenhelm, M. M.
    Lopez, C. D.
    ONKOLOGIE, 2010, 33 : 256 - 256
  • [9] Oncogenic Splicing of the Apoptosis-Stimulating Protein of p53-2 (ASPP2) Is an Initiating Step in Leukemogenesis Facilitating Acquisition of Structural Genomic Mutations
    Kampa-Schittenhelm, Kerstin Maria
    Mau-Holzmann, Ulrike
    Lopez, Charles
    Schittenhelm, Marcus M.
    BLOOD, 2016, 128 (22)
  • [10] Insights Into the Role of ASPP2 (Apoptosis Stimulating Protein of p53-2) in Lymphomagenesis.
    Kampa, Kerstin M.
    Mueller, Sandra
    Bonin, Michael
    Schittenhelm, Marcus M.
    Lopez, Charles D.
    BLOOD, 2009, 114 (22) : 779 - 779
1234